글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종

■ 영문 제목 : Lymphoma Therapeutics Market By Disease Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Treatment Type (Immune Therapy, Chemotherapy, Targeted Therapy, Radiation Therapy), By Route of Administration (Oral Route, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032

Allied Market Research가 발행한 조사보고서이며, 코드는 ALD23SEP105 입니다.■ 상품코드 : ALD23SEP105
■ 조사/발행회사 : Allied Market Research
■ 발행일 : 2023년 4월
■ 페이지수 : 481
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 세계
■ 판매가격 / 옵션 (부가세 10% 별도)
Single UserUSD5,820 ⇒환산￦7,857,000견적의뢰/주문/질문
5 UserUSD6,540 ⇒환산￦8,829,000견적의뢰/주문/질문
Enterprise UserUSD9,870 ⇒환산￦13,324,500견적의뢰/구입/질문
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
세계의 림프종 치료제 시장은 2022년 156억 9,145만 달러로 평가되며 2023년부터 2032년까지 8.4%의 연평균 성장률을 보이며 2032년에는 352억 7,450만 달러에 달할 것으로 예상됩니다. 림프종은 감염 및 기타 질병과 싸우는 데 도움이 되는 면역 체계의 일부인 림프계에 영향을 미치는 암의 일종입니다. 림프종은 림프구라고 하는 특정 유형의 백혈구가 비정상적인 변화를 겪으며 통제할 수 없이 성장하고 증식하기 시작할 때 발생합니다. 림프종 치료제는 림프종을 치료하는 데 사용되는 다양한 유형의 치료제를 말합니다. 다양한 유형의 림프종 치료제에는 화학 요법, 방사선 요법, 면역 요법, 표적 요법, 줄기 세포 이식, 때로는 수술이 포함될 수 있습니다.
림프종 치료제 시장의 성장을 주도하는 주요 요인은 림프종 치료제 파이프라인의 성장입니다. 예를 들어, 2023년 3월 GlobalData 보고서에 따르면 Bayer AG의 황산 라로 트렉티닙은 현재 비호지킨 림프종에 대해 임상 개발 중이며 현재 2 상 단계에 있습니다. 비호지킨 림프종 2상 약물은 3상으로 진행하기 위한 적응증 기준인 상전이 성공률(PTSR)이 40%입니다.
또한 림프종 유병률의 현저한 증가와 노인 인구의 급증은 시장 성장에 크게 기여합니다. 또한, R&D 활동에 대한 투자 증가와 비호지킨 및 호지킨 림프종 치료를 위한 신약 승인에 대한 유리한 정부 정책은 예측 기간 동안 글로벌 시장 성장을 위한 새로운 길을 열 것으로 예상됩니다.

그러나 사용 가능한 치료법의 높은 비용과 림프종에 대한 인식 부족 및 사람들 사이에서 림프종을 치료할 수있는 다양한 옵션의 가용성은 시장 성장을 방해합니다. 반대로, 림프종에 더 취약한 노인 인구의 급증과 환자가 접근 가능하고 안전한 효과적인 의약품의 개발은 예측 기간 동안 시장 성장을위한 수익성있는 기회를 제공 할 것으로 예상됩니다. 

림프종 치료제 시장은 질병 유형, 치료 유형, 투여 경로, 유통 채널 및 지역으로 세분화됩니다. 질병 유형에 따라 시장은 호 지킨 림프종과 비호지킨 림프종으로 나뉩니다. 치료 유형에 따라 면역 요법, 화학 요법, 표적 요법 및 방사선 요법으로 세분화됩니다. 투여 경로에 따라 시장은 경구 경로와 주사제로 분류됩니다. 유통 채널에 따라 병원 약국, 소매 약국 및 온라인 약국으로 구분됩니다. 지역별로 북미, 유럽, 아시아 태평양 및 중남미/중동/아프리카에서 분석됩니다.

북미는 2022년 림프종 치료제 시장 점유율에서 최대 점유율을 차지했으며 예측 기간 동안 지배적인 위치를 유지할 것으로 예상됩니다. 이는 이 지역에서 비호지킨 림프종의 유병률이 증가하고 림프종에 대한 사용 가능한 진단 기술 및 치료 대안에 대한 인구의 인식이 급증했기 때문입니다. 또한, 환급 정책의 가용성과 주요 시장 참여자들의 R&D 활동에 대한 투자 증가로 인한 임상 시험 수의 급증은 시장 성장을 촉진할 것으로 예상됩니다.
아시아 태평양 지역은 노인 인구의 증가와 개발 도상국의 강력한 림프종 약물 파이프 라인으로 인해 예측 기간 동안 가장 빠른 CAGR을 기록 할 것으로 예상됩니다. 또한 인도, 중국, 한국과 같은 개발 도상국에서 림프종의 유병률이 증가하고 림프종에 사용할 수있는 치료 옵션에 대한 인식이 높아짐에 따라이 지역의 시장 성장에 기여하고 있습니다.
림프종 치료제 시장에서 활동하는 주요 업체는 AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lily and Company, F Hoffman La Roche Ltd, Johnson & Johnson, Gilead Sciences, Inc., Seagen Inc., Teva Pharmaceutical Industries Ltd., and Pfizer Inc. 등이 있습니다.

이해관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 림프종 치료제 시장 분석의 시장 부문, 현재 동향, 추정 및 역학에 대한 정량적 분석을 제공하여 지배적인 림프종 치료제 시장 기회를 식별합니다.
시장 조사는 주요 동인, 제약 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 힘을 강조합니다.
림프종 치료제 시장 세분화에 대한 심층 분석은 지배적인 시장 기회를 결정하는 데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 매출 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 글로벌 림프종 치료제 시장 동향, 주요 업체, 시장 세그먼트, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
질병 유형별
호지킨 림프종
비호지킨 림프종

치료 유형별
면역 요법
화학 요법
표적 치료
방사선 요법

투여 경로별
경구 경로
주사제

유통 채널별
병원 약국
소매 약국
온라인 약국

지역별
북미
미국
캐나다
멕시코
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽 지역
아시아 태평양
일본
중국
호주
인도
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ Eli Lilly and Company
○ F. Hoffmann-La Roche Ltd.
○ Bayer AG
○ Johnson & Johnson
○ Teva Pharmaceutical Industries Ltd.
○ AstraZeneca
○ Pfizer Inc.
○ Bristol-Myers Squibb Company
○ Gilead Sciences, Inc.
○ Seagen Inc.
■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 림프종 치료제 시장, 질병 유형별
CHAPTER 5 : 림프종 치료제 시장, 치료 유형별
CHAPTER 6 : 림프종 치료제 시장, 투여 경로별
CHAPTER 7 : 림프종 치료제 시장, 유통 채널별
CHAPTER 8 : 림프종 치료제 시장, 지역별
CHAPTER 9 : 경쟁 현황
CHAPTER 10 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in prevalence of lymphoma
3.4.1.2. Increase in number of drugs in pipeline
3.4.1.3. Rise in number of clinical trials

3.4.2. Restraints
3.4.2.1. High cost of available treatment

3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Hodgkin Lymphoma
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Non-Hodgkin Lymphoma
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Immune Therapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Chemotherapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Targeted Therapy
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Radiation Therapy
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral Route
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Injectable
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Pharmacies
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: LYMPHOMA THERAPEUTICS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Disease Type
8.2.3. Market size and forecast, by Treatment Type
8.2.4. Market size and forecast, by Route of Administration
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Disease Type
8.2.6.1.3. Market size and forecast, by Treatment Type
8.2.6.1.4. Market size and forecast, by Route of Administration
8.2.6.1.5. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Disease Type
8.2.6.2.3. Market size and forecast, by Treatment Type
8.2.6.2.4. Market size and forecast, by Route of Administration
8.2.6.2.5. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Disease Type
8.2.6.3.3. Market size and forecast, by Treatment Type
8.2.6.3.4. Market size and forecast, by Route of Administration
8.2.6.3.5. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Disease Type
8.3.3. Market size and forecast, by Treatment Type
8.3.4. Market size and forecast, by Route of Administration
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Disease Type
8.3.6.1.3. Market size and forecast, by Treatment Type
8.3.6.1.4. Market size and forecast, by Route of Administration
8.3.6.1.5. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Disease Type
8.3.6.2.3. Market size and forecast, by Treatment Type
8.3.6.2.4. Market size and forecast, by Route of Administration
8.3.6.2.5. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Disease Type
8.3.6.3.3. Market size and forecast, by Treatment Type
8.3.6.3.4. Market size and forecast, by Route of Administration
8.3.6.3.5. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Disease Type
8.3.6.4.3. Market size and forecast, by Treatment Type
8.3.6.4.4. Market size and forecast, by Route of Administration
8.3.6.4.5. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Disease Type
8.3.6.5.3. Market size and forecast, by Treatment Type
8.3.6.5.4. Market size and forecast, by Route of Administration
8.3.6.5.5. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Disease Type
8.3.6.6.3. Market size and forecast, by Treatment Type
8.3.6.6.4. Market size and forecast, by Route of Administration
8.3.6.6.5. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Disease Type
8.4.3. Market size and forecast, by Treatment Type
8.4.4. Market size and forecast, by Route of Administration
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Disease Type
8.4.6.1.3. Market size and forecast, by Treatment Type
8.4.6.1.4. Market size and forecast, by Route of Administration
8.4.6.1.5. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Disease Type
8.4.6.2.3. Market size and forecast, by Treatment Type
8.4.6.2.4. Market size and forecast, by Route of Administration
8.4.6.2.5. Market size and forecast, by Distribution Channel
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Disease Type
8.4.6.3.3. Market size and forecast, by Treatment Type
8.4.6.3.4. Market size and forecast, by Route of Administration
8.4.6.3.5. Market size and forecast, by Distribution Channel
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Disease Type
8.4.6.4.3. Market size and forecast, by Treatment Type
8.4.6.4.4. Market size and forecast, by Route of Administration
8.4.6.4.5. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Disease Type
8.4.6.5.3. Market size and forecast, by Treatment Type
8.4.6.5.4. Market size and forecast, by Route of Administration
8.4.6.5.5. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Disease Type
8.4.6.6.3. Market size and forecast, by Treatment Type
8.4.6.6.4. Market size and forecast, by Route of Administration
8.4.6.6.5. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Disease Type
8.5.3. Market size and forecast, by Treatment Type
8.5.4. Market size and forecast, by Route of Administration
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Disease Type
8.5.6.1.3. Market size and forecast, by Treatment Type
8.5.6.1.4. Market size and forecast, by Route of Administration
8.5.6.1.5. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Disease Type
8.5.6.2.3. Market size and forecast, by Treatment Type
8.5.6.2.4. Market size and forecast, by Route of Administration
8.5.6.2.5. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Disease Type
8.5.6.3.3. Market size and forecast, by Treatment Type
8.5.6.3.4. Market size and forecast, by Route of Administration
8.5.6.3.5. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Disease Type
8.5.6.4.3. Market size and forecast, by Treatment Type
8.5.6.4.4. Market size and forecast, by Route of Administration
8.5.6.4.5. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Bayer AG
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Bristol-Myers Squibb Company
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Eli Lilly and Company
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.7. Key strategic moves and developments
10.4. Johnson & Johnson
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Gilead Sciences, Inc.
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Seagen Inc.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.6.7. Key strategic moves and developments
10.7. Teva Pharmaceutical Industries Ltd.
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Pfizer Inc.
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. AstraZeneca
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. F. Hoffmann-La Roche Ltd.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 02. LYMPHOMA THERAPEUTICS MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 03. LYMPHOMA THERAPEUTICS MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 05. LYMPHOMA THERAPEUTICS MARKET FOR IMMUNE THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 06. LYMPHOMA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 07. LYMPHOMA THERAPEUTICS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 08. LYMPHOMA THERAPEUTICS MARKET FOR RADIATION THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 10. LYMPHOMA THERAPEUTICS MARKET FOR ORAL ROUTE, BY REGION, 2022-2032 ($MILLION)
TABLE 11. LYMPHOMA THERAPEUTICS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 13. LYMPHOMA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. LYMPHOMA THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. LYMPHOMA THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 16. LYMPHOMA THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 22. U.S. LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 23. U.S. LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 24. U.S. LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 25. U.S. LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. CANADA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 27. CANADA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 28. CANADA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 29. CANADA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 31. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 32. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 33. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 35. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 36. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 37. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 39. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 40. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 41. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 42. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 44. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 45. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 46. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. UK LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 48. UK LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 49. UK LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 50. UK LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ITALY LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 52. ITALY LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 53. ITALY LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 54. ITALY LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 56. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 57. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 58. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 60. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 64. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 68. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 69. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 70. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 71. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. CHINA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 73. CHINA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 74. CHINA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 75. CHINA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 77. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 78. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 79. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. INDIA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 81. INDIA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 82. INDIA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 83. INDIA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 85. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 92. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 93. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 94. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 95. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 96. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 97. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 98. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 99. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 100. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 101. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 102. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 103. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 104. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 105. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 106. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 107. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 108. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 109. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 110. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 111. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 113. BAYER AG: KEY EXECUTIVES
TABLE 114. BAYER AG: COMPANY SNAPSHOT
TABLE 115. BAYER AG: PRODUCT SEGMENTS
TABLE 116. BAYER AG: PRODUCT PORTFOLIO
TABLE 117. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 118. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 119. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 120. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 121. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 122. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 123. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 124. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 125. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 126. ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 127. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 128. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 129. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 130. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 131. GILEAD SCIENCES, INC.: KEY EXECUTIVES
TABLE 132. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 133. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
TABLE 134. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 135. GILEAD SCIENCES, INC.: KEY STRATERGIES
TABLE 136. SEAGEN INC.: KEY EXECUTIVES
TABLE 137. SEAGEN INC.: COMPANY SNAPSHOT
TABLE 138. SEAGEN INC.: PRODUCT SEGMENTS
TABLE 139. SEAGEN INC.: PRODUCT PORTFOLIO
TABLE 140. SEAGEN INC.: KEY STRATERGIES
TABLE 141. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 142. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 143. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 144. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 145. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 146. PFIZER INC.: KEY EXECUTIVES
TABLE 147. PFIZER INC.: COMPANY SNAPSHOT
TABLE 148. PFIZER INC.: PRODUCT SEGMENTS
TABLE 149. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 150. PFIZER INC.: KEY STRATERGIES
TABLE 151. ASTRAZENECA: KEY EXECUTIVES
TABLE 152. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 153. ASTRAZENECA: PRODUCT SEGMENTS
TABLE 154. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 155. ASTRAZENECA: KEY STRATERGIES
TABLE 156. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 157. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 158. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 159. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 160. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
※본 조사보고서 [글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종] (코드 : ALD23SEP105) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종] 에 대해서 E메일 문의는 여기를 클릭하세요.
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

  • 글로벌 근골격계 질환 (MSD) 치료제 시장 (2023-2032) : 진통제, DMARD, 코르티코 스테로이드, 기타
    ALD23SEP123 / Allied Market Research / 2023년 4월 / 글로벌 근골격계 질환 (MSD) 치료제 시장은 2022년 834억 7,424만 달러 규모였으며 2023년부터 2032년까지 4.2%의 연평균 성장률을 보이며 2032년에는 126억 3,022만 달러에 달할 것으로 예상됩니다. 근골격계 질환(MSD)은 근육, 뼈, 관절에 영향을...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 근골격계 질환(MSD) 치료제 시장, 약품 유형별 CHAPTER 5 : 근골격계 질환(MSD) 치료제 시장, 투여 경로별 CHAPTER 6 : 근골격계 질환(MSD) 치료제 시장, 유통 채널별 CHAPTER 7 : 근골격계 질환(MSD) 치료제 시장, 지역별 CHAPTER 8...
  • 글로벌 죽상동맥경화증 치료제 시장 (2023-2032) : 항혈소판제 및 항응고제, 콜레스테롤 저하제, ACE 억제제, 기타
    ALD23SEP122 / Allied Market Research / 2023년 4월 / 글로벌 죽상동맥경화증 치료제 시장은 2022년 20,608.51백만 달러에 달했으며 2032년에는 27,711.92백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 3%의 연평균 성장률을 보일 것으로 전망됩니다. 죽상동맥경화증은 플라크가 쌓여 동맥 벽이 딱딱해져 정맥이 좁아지는...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 죽상동맥경화증 치료제 시장, 약제 유형별 CHAPTER 5 : 죽상동맥경화증 치료제 시장, 투여 경로별 CHAPTER 6 : 죽상동맥경화증 치료제 시장, 유통채널별 CHAPTER 7 : 죽상동맥경화증 치료제 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER 9...
  • 글로벌 항비만제 시장 (2023-2032) : 처방약, 일반 의약품
    ALD23SEP113 / Allied Market Research / 2023년 4월 / 글로벌 항비만제 시장은 2022년 1,605.36백만 달러 규모였으며, 2023년부터 2032년까지 10.7%의 연평균 성장률을 보이며 2032년에는 4,439.34백만 달러에 달할 것으로 예상됩니다. 비만은 건강에 부정적인 영향을 미칠 정도로 체지방이 과도하게 축적된 의학적 상태입니다....CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 항비만제 시장, 약품 유형별 CHAPTER 5 : 항비만제 시장, 작용 기전별 CHAPTER 6 : 항비만제 시장, 투여 경로별 CHAPTER 7 : 항비만제 시장, 유통 채널별 CHAPTER 8 : 항비만제 시장, 지역별 CHAPTER 9 :...
  • 글로벌 혈전 용해제 시장 (2023-2032) : 혈전 용해제, 항혈소판제, 항응고제, 항응고제, 기타
    ALD23SEP170 / Allied Market Research / 2023년 6월 / 글로벌 혈전 용해제 시장은 2022년 28,616.4억 달러에서 2023년부터 2032년까지 8.2%의 연평균 성장률로 성장하여 2032년에는 60,009.20억 달러에 달할 것으로 예상됩니다.혈전 용해제 또는 섬유소 용해제라고도 하는 혈전 용해제는 혈전증이라는 의학적 질환에서 혈전을...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 혈전 용해제 시장, 제품별 CHAPTER 5 : 혈전 용해제 시장, 질환별 CHAPTER 6 : 혈전 용해제 시장, 투여 경로별 CHAPTER 7 : 혈전 용해제 시장, 유통 채널별 CHAPTER 8 : 혈전 용해제 시장, 지역별...
  • 글로벌 제네릭 의약품 시장 (2023-2032) : 심혈관, 감염, 암, 당뇨병, 기타
    ALD23SEP154 / Allied Market Research / 2023년 6월 / 글로벌 제네릭 의약품 시장은 2022년에 385,320,00백만 달러로 평가되었으며 2032년에는 835,706,50백만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 8.1%의 연평균 성장률을 보일 것으로 전망됩니다.제네릭 의약품은 용량 형태, 효능, 투여 방식, 품질, 성능...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 제네릭 의약품 시장, 치료 용도별 CHAPTER 5 : 제네릭 의약품 시장, 투여 경로별 CHAPTER 6 : 제네릭 의약품 시장, 유통 채널별 CHAPTER 7 : 제네릭 의약품 시장, 지역별 CHAPTER 8 : 경쟁 현황 CHAPTER...